Biosimulation Market Is Poised To Reach Around $3.77 Billion By 2024: Grand View Research, Inc.

The biosimulation market is expected to reach USD 3.77 billion by 2024, according to a new study by Grand View Research, Inc. The unprecedented global shift in the adoption of unhealthy lifestyles is resulting in the high prevalence of chronic diseases, such as cancer and diabetes, is expected to drive the biosimulation market during the forecast period. 

In addition, the rising geriatric population base highly susceptible to acquire the aforementioned chronic diseases result in enhanced demand for highly efficacious pharmacological drugs. This high requirement of efficacious drugs can be effectively met at a faster rate through the incorporation of the in silico approach, thus creating a high potential for biosimulation market growth opportunities in the future. Furthermore, increasing drug resistance, high drug failure rate, and availability of limited drugs to treat several diseasessuch as AIDS, pneumonia, tuberculosis, and others indicate the indisputable requirement for the incorporation of biosimulation in the drug discovery and development process. The widespread application of the in silico approach to developing efficacious drugs would generate drugs of greater potency in the market within a shorter span.
North America Biosimulation Market Share, by Application, 2014 - 2024 (USD Million)


The increasing demand can be attributed primarily to the significant cost reduction in the clinical trials and drug development & discovery process. This is due to the fact that the in silico software can predict adverse reactions, toxicity, and efficacy of the drugsin the early stages of the drug development, thereby reducing the probability of drug failure at the later stages and consequentially, control the overall expenditure. These above-mentioned factors serve as key reasons responsiblefor the heightened market demand.

Browse full research report on Biosimulation Market: https://www.grandviewresearch.com/industry-analysis/biosimulation-industry 

                                   
Further key findings from the report suggest:

  • The services segment is expected to exhibit growth at a significant CAGR of over 16.0% during the forecast period. This is a consequence of rising inclination of the big pharmaceutical companies to outsource their biosimulation process so as to reduce the overall cost incurred in research and development and divert its focus toward their core capabilities.
  • The drug discovery segment is anticipated to witness an exponential CAGR of over 15.0% in the application segment. Associated benefits of biosimulation in drug discovery are anticipated to fuel the demand over the forecast period. These benefits include the elimination of potential drug failures, predict unfavorable drug interactions, and anticipate potential risks.
  • In addition to these, certain other advantages include increased drug efficacy through the evaluation of optimal synergistic combinations, enable study of the mechanistic actions of drugs, and identification ofthe most suitable dosage forms, which render the drug discovery segment a profitable zone.
  • In 2015, the pharmaceutical and biotechnology companies held a substantial share of this vertical of over 58.0% in 2015. This can be attributed to the consistent efforts of these companies to develop better medication options at a faster and cheaper rate through in silico biology techniques.
  • Likewise, the academic research applications are presumed to witness constant growth as a consequence of the presence of various academic research groups that are involved in the study of complex biological systems using computer models, such as by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
  • In 2015, North America dominated the overall biosimulation marketat over 50.0%. The presence of regulatory authorities, consistently inclined towards ensuring patient safety, is a crucial factor presumed to be responsible for the dominant market share ofthis region. Moreover, the presence of highly skilled professionals also serves as a significant growth driver.
  • The numerous collaborations amongst the leading playersthat are being undertaken to promote the incorporation of biosimulation systems are expected to be responsible for bolstering the growth inthis region. For instance, Entelos, Inc. collaborated with Bayer AG to develop novel gene-based drug targets and also with Johnson & Johnson, Inc. to optimize clinical trial designs through in silico models.
  • Some of the leading players in this industry include Certara USA, Inc., Simulation Plus, Inc., Dassault Systems SA, Rhenovia Pharma Ltd., and Evidera, Inc. These players are actively involved in initiating collaborative strategies and frequent product launches to capture a larger share of the vertical.For instance, In April 2016, Simulation Plus, Inc. launched the DDDPlus Version 5.0, invitro dissolution experiment software. This upgraded version includes improvements in functionalities of the software that enable scientists and researchers to study the behavior of different pharmaceutical dosage forms.

Browse more reports of this category by Grand View Research: https://www.grandviewresearch.com/industry/healthcare-it    
                           
Grand View Research has segmented the biosimulation marketon the basis of product, application,enduse and region:

Global Biosimulation Product Outlook (Revenue, USD Million, 2013 - 2024)
  • Software
  • Services
    • In-house Services
    • Contract Services
Global Biosimulation Application Outlook (Revenue, USD Million, 2013 - 2024)
  • Drug Development
  • Drug Discovery
  • Others
Global Biosimulation End-use Outlook (Revenue, USD Million, 2013 - 2024)
  • Pharmaceutical & Biotechnology Companies
  • CROs
  • Regulatory Authorities
  • Academic Research Institutions
Biosimulation Regional Outlook (Revenue, USD Million, 2013 - 2024)
  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Mexico
    • Brazil
  • MEA
    • South Africa

Access Press Release By Grand View Research: https://www.grandviewresearch.com/press-release/global-biosimulation-market                                                     

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


For more information: http://www.grandviewresearch.com

Comments

Popular posts from this blog

The global vein illuminator market is expected to reach USD 358.5 million by 2024, according to a new report published by Grand View Research, Inc. The vein illuminator market is anticipated to witness a lucrative growth during the period 2016 to 2024. The factors contributing towards the growth of the market are the growing aging population and the efforts channelized towards improving patient satisfaction. Additionally, factors, such as the demand for technologically advanced medical equipment and the rising research and practical applications are expected to be opportunistic for the industry growth. However, the prevalence of traditional methods owing to the high costs of the vein illuminator devices is likely to hinder the growth of the market in the near future. The vein illuminator market is segmented on the basis of technology, application, end-user, and region. Based on technology, the market is further categorized into transillumination, infrared technology, and ultrasound. The near-infrared illumination technology is estimated to be the largest shareholder due to its ability to penetrate deep into the tissue, which makes it possible to visualize the vessels clearly. On the basis of application, the market is segmented into intravenous access and blood draw. The end-user segment comprises hospitals, rehabilitation facilities, blood donation camps, and academic institutions. The market for hospitals is expected to grow rapidly during the forecast period due to a surge in the demand for technologically advanced medical equipment. The market is also categorized into North America, Europe, Asia Pacific, MEA, and Latin America. Browse full research report on global Vein Illuminator Market: http://www.grandviewresearch.com/industry-analysis/vein-illuminator-market Further key findings from the study suggest: • In terms of market share, the North America vein illuminator market is expected to hold majority of the share in 2016. Factors resulting in the growth of this industry are the steady preference for highly-advanced medical devices by hospitals as well as the presence of several medical device manufacturing companies in the region. • The infrared illumination technology is estimated to lead the industry due to its deep penetration capability into thick tissues tohighlight the presence of vessels with increased clarity. Based on application, the segment for intravenous access is estimated to be the largest shareholder, followed by the blood draw segment. • The vein illuminator industry comprises several local as well as global players. Some prominent players in this industry include Accuvein, Inc., Christie Medical Holdings, Inc., Infrared Imaging Systems, Inc., Translite, LLC, and Venoscope, LLC,among others. In order to hold a major share in the industry, the companies are adopting both organic as well as inorganic strategies. The major strategies adopted by the companies are new product development, mergers, collaborations, partnerships, geographical expansions, and acquisitions. • The companies are also focusing on research and development activities in order to enhance their product portfolio. For instance, in September 2015, Accuvein, Inc., declared its 26th patent, which was issued by the United States Patent and Trademark office for their vein visualization system. Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices Grand View Research has segmented the vein illuminator market on the basis of technology, application, and end-user application: Vein Illuminator Technology Outlook (Revenue, USD Million, 2013 - 2024) • Transillumination • Infrared technology • Others Vein Illuminator Application Outlook (Revenue, USD Million, 2013 - 2024) • Intravenous access • Blood draw • Others Vein Illuminator End-user Outlook (Revenue, USD Million, 2013 - 2024) • Hospitals • Blood donation camps • Academic institutions • Others Vein Illuminator Regional Outlook (Revenue, USD Million, 2013 - 2024) • North America • Europe • Asia Pacific • Latin America • MEA Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-vein-illuminator-market About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc For more information: www.grandviewresearch.com

Hyaluronic Acid Market Is Likely To Be Influenced By The Increase In Obesity Till 2024: Grand View Research, Inc.

Protein Purification & Isolation Market Is Predicted To Grow Swiftly Due To Increased Research In The Fields Of Biotechnology & Pharmaceuticals Till 2025: Grand View Research, Inc.